Jazz Pharmaceuticals (JAZZ) Faces A Fresh Valuation Test Following Mixed Earnings And Buyback
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
Jazz Pharmaceuticals recently reported mixed Q3 2026 earnings with a revenue increase but a net loss, alongside a new US$500 million share repurchase plan. Despite a 75% one-year total return, its US$248 share price is considered 16% undervalued by analysts, who estimate a fair value of $294.27, partly due to expected expansion of Ziihera.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.